eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2024
vol. 41
 
Share:
Share:
abstract:
Review paper

Afamelanotide in protoporphyria and other skin diseases: a review

Adriana Polańska
1
,
Joanna Wegner
2
,
Paula Nutbohm
2
,
Petra Staubach
2
,
Ryszard Żaba
1
,
Aleksandra Dańczak-Pazdrowska
1
,
Dorota Jenerowicz
1

  1. Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Dermatology, University Medical Center Mainz, Mainz, Germany
Adv Dermatol Allergol 2024; XLI (2): 149-154
Online publish date: 2024/04/12
View full text Get citation
 
Afamelanotide is a synthetic alpha melanocyte stimulating hormone presenting a higher activity than natural hormones. Its main properties are related to the enhanced production of eumelanin by agonistically binding to the melanocortin-1 receptor. Since 2016 afamelanotide has been especially applied to treat cases of erythropoietic porphyria (EPP), where painful photosensitivity has been observed since early childhood. The positive effect of afamelanotide in EPP administered subcutaneously improved tolerance to artificial white light and increased pain-free time spent in direct sunlight. In this review we summarize the possible use of afamelanotide in dermatology, with special emphasis on EPP and encourage including afamelanotide as a treatment option in patient care.
keywords:

afamelanotide, protoporphyria, erythropoietic porphyria

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.